Pharmaceuticals

ERMA Systems is launching a key AI pilot to modernize pharma's regulatory review process, adding a rare disease expert to its board for its 2026 rollout.

Merck's former R&D IT head Matt Studney joins TetraScience, a move highlighting biopharma's critical pivot from fragmented data to industrial-scale AI.

International Healthcare Week 2026 will unite pharma, medtech, and labs, aiming to transform healthcare for 700 million people across Southeast Asia.

The Korean biopharma giant is leveraging its biosimilar success to fund a major push into cutting-edge cancer therapies and advanced drug platforms.

Flashpoint Therapeutics appoints an FDA-approved drug developer as CSO, a strategic move to accelerate its groundbreaking structural nanomedicine platform.

From developing neonatal ventilators to pivotal COVID vaccine research, a San Antonio institute marks 85 years on the front lines of global health.

MIT economist Andrew Lo joins the Global Coalition for Adaptive Research, bringing Wall Street strategies to revolutionize clinical trials for rare diseases.

A new alliance in healthcare marketing merges pharmaceutical expertise with provider-side insights, leveraging AI and big data to fix a fragmented system.

A new celebrity-backed eye drop promises freedom from reading glasses. We look at the science, the competition, and what it means for 128M Americans.

A new AI solution promises to automate a critical manufacturing step, tackling costly errors and downtime that plague the life sciences industry.

With new data showing six-month efficacy and a unique liquid formula, Galderma's Relfydess is poised to challenge established players in the neuromodulator space.

A coalition of top GOP senators and state attorneys general is urging the FDA to pull mifepristone, escalating the fight over abortion to the federal level.

With new funding from BroadOak Capital Partners, Axol Bioscience is set to expand its revolutionary iPSC-based disease models in the US market.

Moving beyond hype, ArisGlobal's record growth and enterprise adoption of its NavaX AI show the pharmaceutical industry is now operationalizing AI at scale.

With a new finance head, the non-profit plans to launch a breakthrough vitamin A product in Africa, blending philanthropy with commercial strategy.

The biopharma firm projects massive sales from its current drugs and bets big on a new Alzheimer's therapy, signaling a pivotal year of growth and innovation.

Kye Pharma brings SLENYTO®, a first-of-its-kind prescription sleep aid, to Canada, offering relief to children with ASD and SMS and their families.

MedTech firm Lifeward is acquiring Oramed's oral insulin tech, despite a past trial failure, in a high-stakes deal that could redefine both companies.

A new partnership aims to tackle the growing global health crisis of invasive fungal infections, a silent killer claiming millions of lives annually.

Aptar's 'Beat the Blink' technology, in partnership with Bausch + Lomb, promises to solve the age-old problem of inaccurate eye drop dosing.